Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Read also

Eli Lilly

Eli Lilly picks Virginia for $5bn drug manufacturing plant

Modus

Modus data on sevuparin for CKD to be presented at global GAG symposium

Biocon Biologics

Biocon Biologics Says FDA Approves Bosaya And Aukelso As Denosumab Biosimilars

Nurix reports

Nurix reports promising preclinical data for IRAK4 degrader GS-6791